Published Medical Literature

Does Race Influence Treatment Opportunities for Men With Prostate Cancer?

Can FSH Levels Influence Oncogenic and Cardiovascular Outcomes in Men With Prostate Cancer?

Multimodal Treatment and Mortality Outcomes in High-Risk Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer: Reconsidering the Role of Olaparib

Is Radiotherapy of Benefit for Men With Prostate Cancer and Inflammatory Bowel Disease?

Radioligand Therapy Plus Standard Care for Metastatic Castration-Resistant Prostate Cancer

Swedish Simulation Model Study in Prostate Cancer: Focus on PSA Testing

Prognostic Factors for Decisional Regret Regarding Treatment in Localized Prostate Cancer

PSA Velocity and Disease Progression in Black Versus Non-Hispanic White Men With Prostate Cancer

Potential Role of 11-Ketotestosterone in Castration-Resistant Prostate Cancer

Mortality Risk and PSA Failure in Localized Versus Locally Advanced Prostate Cancer

Environmental Quality and Stage of Prostate Cancer at Diagnosis

Can Genomic Testing Impact Treatment Choice for Low-Risk Prostate Cancer?

Does Race Affect Response to Treatment in Metastatic Castration-Resistant Prostate Cancer?

ctDNA-Targeted Sequencing in Metastatic Prostate Cancer: Real-World Chinese Study

Leuprolide Acetate for Prostate Cancer: Achieving Effective Testosterone Suppression

Is Dietary Acrylamide Intake Associated With the Development of Prostate Cancer?

Early Detection of Aggressive Prostate Cancer: Urine-Based Multibiomarker Test Under Study

AR-V7–Positive Prostate Cancer: Phase II Trial of Combination Immunotherapy

PSA Testing Versus MRI or Ultrasonography in Detecting Clinically Significant Prostate Cancer

Bipolar Androgen Therapy Versus Enzalutamide in Castration-Resistant Prostate Cancer

Updated ASCO Guideline: First-Line Management of Advanced Prostate Cancer

Stereotactic Body Radiotherapy for High-Risk Localized Prostate Cancer

Capivasertib Plus Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

Effect of Androgen-Deprivation Therapy on Systemic Symptomatology in Men With Prostate Cancer

Initial Systematic Biopsy Versus MRI for Detection of Clinically Significant Prostate Cancer

Plasma Cells and Immune Responsiveness in Black Men With Prostate Cancer

Active Surveillance for Early-Stage Prostate Cancer: Risk Factors for Metastases

Quality-of-Life Comparisons for Two Radiotherapies for Localized Prostate Cancer

Does Delaying Surgery Affect Outcomes in Localized High-Risk Prostate Cancer?

Do GnRH Agonists for Prostate Cancer Increase Risks for Dementia and Parkinson’s Disease?

Novel Clinical Prognostic Stage Group System for Prostate Cancer

Variable Regional Adoption of Genomic Testing for Prostate Cancer

Does Warfarin Exposure Decrease the Risk for Prostate Cancer?

Link Between Coffee Consumption and Risk for Prostate Cancer?

Conventionally Fractionated Versus Ultrahypofractionated Radiotherapy in High-Risk Localized Prostate Cancer

Salvage Radiotherapy for Prostate Cancer: Is Elevated PSA After Surgery Linked to Poor Outcomes?

Radiotherapy for Men With Prostate Cancer: Consider History of Medication Allergies

SIRT3 Expression in Metastasis of Prostate Cancer to the Bone

Emerging Role of Hemigland Cryoablation With MRI-Guided Biopsy for Prostate Cancer

Neoadjuvant Chemohormonal Therapy With Radical Prostatectomy for Localized Prostate Cancer

Current Perspective on Management of Advanced Prostate Cancer: ‘Abundance of First-Line Options’

Racial Disparities in Prostate Cancer Deaths: Potential Contributing Factors

Conservative Management of Prostate Cancer in Veterans: Racial Comparison

Is BMD Testing After Treatment for Prostate Cancer Meeting Guideline Recommendations?

Expert Panel Offers Practical Guide for Managing Castration‐Resistant Prostate Cancer

Does Androgen-Deprivation Therapy for Prostate Cancer Increase Risk of Dementia?

Enzalutamide Treatment for Prostate Cancer: Still Beneficial After Disease Progression?

Adjuvant Radiotherapy Versus Early Salvage Radiotherapy in Localized Prostate Cancer

Update on Trends in Initial Management of High-Risk Prostate Cancer

Prostate Cancer and Type 2 Diabetes: Focus on Outcomes and Metformin

Can Prostate Cancer Surveillance Be Tailored to Individual Risk?

Preradiation Testosterone Levels and Aggressiveness of Prostate Cancer

Mediterranean Diet and Prostate Cancer–Related Fatigue

Radiotherapy for Localized Prostate Cancer: Is Event-Free Survival Suitable Surrogate for Overall Survival?

Rucaparib in BRCA-Mutant Metastatic Prostate Cancer: TRITON2 Trial

Long-Term ADT for Prostate Cancer: Cognitive Function and Decision-Making

Updated ESMO Guidelines for Management of Prostate Cancer

Ultrahypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer

African Ancestry–Specific Variant May Be Linked to Familial Prostate Cancer Risk

First-in-Human Phase I Trial of Novel Vaccine in Metastatic Prostate Cancer

Surgery Versus Multimodal Radiotherapy for High-Risk Localized Prostate Cancer

Docetaxel Plus ADT in Minority Patients With Prostate Cancer

Does Radium-223 Improve Survival in Older Men With Metastatic Castration-Resistant Prostate Cancer?

Study Finds Regional Variations in Race-Based Survival Differences in Prostate Cancer

PSMA PET-CT Versus Conventional Imaging for Aggressive Prostate Cancer

Does Relugolix Reduce Testosterone Levels in Men With Advanced Prostate Cancer?

Adding Docetaxel to Standard Treatment of Localized High-Risk Prostate Cancer

PARP Inhibition in Men With Resistant Prostate Cancer

Can PSA Levels Before Salvage Radiotherapy Predict Outcomes in Men With Prostate Cancer?

Urinary Biomarkers in Detection of Prostate Cancer

Is ADT Protective Against SARS-CoV-2 Infection in Men With Prostate Cancer?

Conventional Fractionated Versus Hypofractionated Radiation for Prostate Cancer: A 10-Year Update

Height/Weight in Early Adulthood and Risk of Prostate Cancer

Concurrent Enzalutamide, Salvage Radiotherapy, and ADT in High-Risk Prostate Cancer

Link Between Polypharmacy and Inpatient Hospitalization in Older Patients With Prostate Cancer?

Racial Differences in Telomere Length in Prostate Cancer Cells

Can Tomato Consumption Reduce the Risk of Prostate Cancer?

Could a Low-Carb Diet Improve PSA Levels in Prostate Cancer?

Is Testosterone-Related Genetic Variant Linked to Poor Outcomes in Men With Prostate Cancer?

Comparing Radiation Therapies for Gleason 5 Prostate Cancer

Combined Biopsy Approach to Prostate Cancer Detection

Comparing Radiotherapies for Nodal Oligorecurrent Prostate Cancer

Salvage Radiotherapy Plus Androgen Deprivation After Surgery for Prostate Cancer

Risk of New Persistent Opioid Use After Minor Urologic Procedures

Neural Transcription Factor: Driver for Castration-Resistant Prostate Cancer?

Adverse Reactions to Treatments of Localized Prostate Cancer: A 5-Year Study

Artificial Intelligence and the Detection and Grading of Prostate Cancer

Do Genomic Markers Correlate With Subclassification of High-Risk Prostate Cancer?

Early-Phase Study of Antibody-Drug Conjugate in Castration-Resistant Prostate Cancer

Can Statins Lower the Risk of Aggressive Prostate Cancer?

Novel Biomarker for Early Prostate Cancer Under Study

Prospective Implications of BRCA Mutations in Prostate Cancer

Does Adjuvant Docetaxel Improve Biochemical Disease–Free Survival in Prostate Cancer?

Circulating Tumor DNA in Localized and Advanced Prostate Cancers

Study Finds Conservative Management of Prostate Cancer Varies Among Group Practices

Study Explores Link Between Diet and Prostate Cancer Risk

Use of Complementary and Alternative Medicine in Patients With Prostate Cancer

Updated Results From SPARTAN Trial on Apalutamide in Prostate Cancer

Small Cell Carcinoma of the Prostate: Update on Patterns of Care

Comparison of Radiation Therapies for Prostate Cancer Based on Quality of Life

Comparing Adjuvant and Early Salvage Radiotherapy for Prostate Cancer After Surgery

Insurance and Mortality in Prostate and Other Cancers

Incident Risk of Prostate Cancer and Mushroom Consumption

Comparing Imaging Modalities in Detecting Biochemical Recurrence of Prostate Cancer

Enzalutamide/ADT in Metastatic Hormone-Sensitive Prostate Cancer: ARCHES Trial

Should Stereotactic Body Radiation Therapy Be Standard Option in Localized Prostate Cancer?

Does Radical Prostatectomy Affect Sexual Interest and Satisfaction?

Cardiovascular Effects of Androgen-Deprivation Therapy in Prostate Cancer

Ultrahypofractionation Versus Conventional Fractionation in Prostate Cancer

Including Pelvic Lymph Nodes in Radiation Fields for Advanced Prostate Cancer: Update on Toxicity

Preventing Skeletal Fractures in Patients Treated for Metastatic Prostate Cancer

World Trade Center First Responders: Cause of Increased Risk of Prostate Cancer Explored

Can Repeated PSA Screening Reduce Prostate Cancer Mortality?

Inguinal Hernia After Minimally Invasive Radical Prostatectomy

LATITUDE Trial: Final Survival Data on Abiraterone Acetate and Prednisone Plus ADT

Radiotherapy After Prostatectomy: Updated Joint Clinical Guidance by ASTRO and AUA

Adding Docetaxel to Standard Treatment in High-Risk Prostate Cancer

Is There an Association Between Black Race and Mortality From Prostate Cancer?

Neoadjuvant Hormone Therapy Before Prostatectomy in Locally Advanced Prostate Cancer

Study Finds Docetaxel May Benefit Some Patients With Prostate Cancer

Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis

AR-V7 Assays and Treatment Outcomes in Castration-Resistant Prostate Cancer

Combining Approved Treatments in Metastatic Castration-Resistant Prostate Cancer

Viral Vector–Based Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Duration of ADT With Radiation After Prostatectomy Depends on Risk Factors

Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer

ARAMIS Trial: Darolutamide in Nonmetastatic Prostate Cancer

Risk of Dementia From Androgen-Deprivation Therapy for Prostate Cancer

LATITUDE Trial: Survival Benefit With Combination Therapy for Prostate Cancer

Lipid-Lowering Medication and Risk of Prostate Cancer

Active Surveillance vs. Radical Treatment of Prostate Cancer

Impact of Race on Survival in Metastatic Castration-Resistant Prostate Cancer

Androgen-Deprivation Therapy for Prostate Cancer: Managing Cardiovascular Risks

Health-Related Quality of Life in Men With Advanced Versus Localized Prostate Cancer

Computer-Simulated Study Suggests Enlarged Prostate May Actually Hinder Tumor Growth

Is Time to Biochemical Failure a Surrogate Endpoint in Locally Advanced Prostate Cancer?

Duration of Androgen Suppression and Zoledronic Acid in Locally Advanced Prostate Cancer

Does Apalutamide Negatively Impact Quality of Life in Nonmetastatic CRPC?

AUA Guideline Amendment for Castration-Resistant Prostate Cancer

Closer Look at Types of Prostatectomy and Quality of Life

Does Androgen-Deprivation Therapy Increase Risk of Heart Failure in Men With Prostate Cancer?

Can Tyrosine Kinase Inhibitors for CML Affect PSA Titers Unrelated to Prostatic Disease?

Assessing Combination of Osteoprotective Agents and Anticancer Drugs in Prostate Cancer

Early Research on Birabresib in Prostate Cancer and Other Solid Tumors

Noninvasive Diagnosis of Prostate Cancer Using Novel Imaging Technique

Long-Term Results With Hormonal Therapy Plus Radiotherapy in Prostate Cancer

Active Surveillance for Prostate Cancer: Are Patients Being Lost to Follow-up?

PSA Screening for Prostate Cancer: Does It Really Reduce Disease-Specific Mortality?

Coffee Consumption and Disease-Free Progression in Patients With Localized Prostate Cancer

Are Researchers Closer to Diagnosing Aggressive Prostate Cancer at an Early Stage?

Rebiopsy for Prostate Cancer: Can Some Men With Negative MRI Avoid It?

Does Enzalutamide Affect Metastasis-Free Survival in Men With Aggressive Prostate Cancer?

Can Hypofractionated Radiotherapy Improve Prostate Cancer Control?

Low Free Testosterone Concentration May Equal Low Prostate Cancer Risk

Survival Impact of Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Does Surgical Technique Affect Outcomes in Patients With Prostate Cancer?

New Prognostic Imaging Biomarker in Metastatic Prostate Cancer

Report Sheds Light on Trends in Prostate Cancer

Pharmacoeconomic Implications of Low-Dose Abiraterone in Castration-Resistant Prostate Cancer

Predictors of Urinary Function After Prostatectomy

Updated USPSTF Screening Guidelines for Prostate Cancer

Timing of Catheter Removal After Robot-Assisted Radical Prostatectomy

Clinical Associations of Luminal and Basal Subtyping in Prostate Cancer

ASCO Clinical Practice Guidelines for Metastatic Noncastrate Prostate Cancer

Robot-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer

Dose-Escalated Radiation Therapy for Intermediate-Risk Prostate Cancer

After Disease Progression on Enzalutamide, Can Bipolar Androgen Therapy Make a Difference in Prostate Cancer?

SPARTAN Trial: Apalutamide in Nonmetastatic Prostate Cancer

Radiotherapy Versus Surgery for High-Risk Localized Prostate Cancer

Health-Related Quality of Life After Radical Prostatectomy